NIH trial to evaluate new antiviral in adults hospitalized with COVID-19

NIH has launched a multi-site clinical trial in the U.S. to investigate Shionogi's new oral antiviral S-217622 (or ensitrelvir fumaric acid) for the treatment of COVID-19 in hospitalized patients. S-217622 is the first agent to be evaluated in a new global, adaptive clinical research protocol known as Strategies and Treatments for Respiratory Infections & Viral Emergencies (STRIVE).